CD274 and head and neck squamous cell carcinoma: embarked on a clinical trial assessing preoperative immunotherapy using the programmed cell death ligand 1 (PD‐L1) inhibitor atezolizumab in patients diagnosed with locally metastatic head and neck squamous cell carcinoma (HNSCC).